Connect with us

Markets & Industry

Where can I find training for psychedelic therapy?



Where can I find training for psychedelic therapy?
Photo by Rohit Tandon on Unsplash

With psychedelics and psychedelic-assisted psychotherapy showing promise as potential treatments for mental health conditions, skilled facilitators who can provide therapy for patients and in clinical trials is vital.

Around one in six adults in England, UK and one in five adults in the US are living with a mental health condition. To add to this, around 30% of people with major depressive disorder do not respond to current pharmaceutical treatments such as SSRI’s and traditional talking and cognitive therapies. 

With this desperate need for innovation in mental health care, there has been a blossoming of interest in psychedelic compounds as possible alternative treatments.

See also  Psychedelic facilitators graduate from training programme

The growing number of psychedelic clinical research, trials and academic centres for psychedelic research has increased the demand for therapists who are experienced in the delivery of psychedelic care, leading to the creation of an array of educational and training courses.

Courses that are now available focus on the likes of psychedelic-assisted psychotherapy, medical psychedelics education and integrative therapy, for example, and provide counsellors with the opportunity to become certified psychedelic practitioners.

See also  Educating stewards of psychedelic medicine

Here is just a selection of courses that are currently available.


MDMA-assisted therapy for post-traumatic stress disorder (PTSD) has been designated by the FSA as a Breakthrough Therapy, and The Multidisciplinary Association of Psychedelics (MAPS) has spearheaded much of the research around MDMA.

Whilst the organisation also researches psychedelics such as ibogaine and ayahuasca, its work with MDMA is globally recognised as leading in the field, and the organisation has created a manual for the delivery of MDMA-assisted therapy along with a Code of Ethics for Psychedelic Psychotherapy.

MAPS MDMA Therapy Training Program covers the theory, skills and practice of MDMA-assisted therapy and offers the opportunity for scholarships.

To learn about this course please visit:

The California Institute of Integral Studies (CIIS)

CIIS offers a certificate in Psychedelic-Assisted Therapies and Research at its Center for Psychedelic Therapies and Research.

The CIIS states that the course emphasises the therapeutic models of psychedelic research while also addressing the philosophy and theory from other scholarly traditions, with the course curriculum being developed by Janis Phelps, Director of the Center for Psychedelic Therapies and Research, in collaboration with clinicians and researchers in the field of psychedelic healthcare.

To learn about this course please visit:

COMPASS Pathways

COMPASS pathways is a leading company in the field of psychedelic research, focusing on the likes of using psilocybin-assisted psychotherapy for the treatment of resistant depression. 

The company’s therapist training programme has been designed by leading experts and was used to train therapists taking part in its Phase 2b clinical trial of psilocybin therapy for treatment-resistant depression.

The training consists of 10+ hours of online learning, five days of interactive learning, clinical training while supporting participants in at least four psilocybin research sessions and continuous professional development.

To learn about this course please visit:

Psychedelics Today

Psychedelics Today’s course, Navigating Psychedelics: Lessons on Self-Care & Integration, offers learners the opportunity to gain a variety of knowledge on psychedelics.

Aspects of the course cover substance testing for improved safety, different approaches to psychedelic use such as microdosing and ceremonial use, how to handle difficult psychedelic experiences, personal integration and more.

To learn about this course please visit:


Education platform, Fluence, offers professional education in psychedelic-assisted psychotherapy and integration.

It states that its programmes have been designed for licensed professionals and advanced graduate students, with some classes and programmes reserved for licensed clinicians. The platform offers students the option to purchase an APA CE and/or CME certificate.

All of Fluence’s training is delivered “independently and in collaboration with a variety of clinics, conferences, private practices, non-profit associations, retreat centres, and psychedelic research sponsors.”

 To learn about this course please visit:

Institute of Psychedelic Therapy

The Institute of Psychedelic Therapy offers a two-year psychedelic-assisted therapist training programme.

The training will provide participants with the opportunity to develop the skills to become safe and compassionate psychedelic practitioners, and graduates of the course will become professional members of the Institute of Psychedelic Therapy.

The first cohort for the course will complete in December 2023 and the next cycle will start in March 2024. 

The Institute requests that, in order to be eligible for the course, applicants must have completed a clinical or therapeutic training of some kind and be registered with an accountable body.

To learn more about this course please visit:

MIND Foundation

The MIND Foundation – a European non-profit science and education organisation promoting psychedelic research and therapy – is offering professional training for aspiring psychedelic therapists.

The organisation’s two-year Augmented Psychotherapy Training (APT) programme is directed at medical doctors, psychotherapists, and complementary mental health professionals and covers the skills needed to practice psychedelic-augmented psychotherapy and psychedelic integration therapy.

To find out more about this course please visit:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Markets & Industry

Psychedelic therapy programmes launch to address heartbreak, burnout and more



Psychedelic therapy programmes launch to address heartbreak, burnout and more

Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges. 

Led by and developed with leading experts in the field, each programme combines specialised teachings with ketamine therapy.

All programmes will include six ketamine therapy sessions focusing on a specific mental health issue, expert-led audio, video, and written content for preparation, treatment, and integration, practical tools such as meditation, one-on-one coaching and group integration sessions.

See also  Psychedelics for frontline workers, palliative care and eating disorders

The first programme in the Series is ‘Recovering from Rejection and Failure’, led by Dr Guy Winch who is a leading authority on emotional health, and a best-selling author and TED speaker whose talks have received over 30 million views.

Winch’s programme focuses on healing and preventing emotional injuries that people suffer in their personal, professional and romantic lives.

Mindbloom CEO and Founder Dylan Beynon stated: “More than 100 studies and 20 plus years of clinical use show that ketamine therapy may be the most transformational mental health treatment available today.

“In the face of epidemics of mental illness, addiction, and loneliness, we’re thrilled to offer our clients access to top experts across a range of issues – and to pair their expertise with our best-in-class ketamine therapy honed over hundreds of thousands of treatment sessions.”

“Emotional wounds like rejection and failure can be even more devastating than physical wounds, yet we don’t give them the same time and attention,” added Dr Winch.

“I’m thrilled to combine my techniques for emotional first aid with ketamine therapy, which has been shown to increase neuroplasticity and help build emotional resilience.”

Additional Mastermind programmes will be released in the coming months, including: Getting Unstuck, by Dr Elizabeth Lombardo; Beating Burnout, by Dr Shauna Shapiro; and Coping with Cravings, by Dr Jud Brewer

“Americans are struggling with heartbreak, burnout, and other challenges every day, and they’re looking for new tools to address them,” said Mindbloom’s Medical Director Dr Leonardo Vando.

“I’m grateful to these experts for providing Mindbloom’s clients with the unique practices and insights they’ve cultivated during their distinguished careers, to help them overcome the biggest obstacles in their lives.”

Continue Reading

Markets & Industry

Mychedelica launches to revolutionise psychedelic medicine



Mychedelica launches to revolutionise psychedelic medicine

A new company specialising in psychedelic medicine – mychedelica – is offering a comprehensive suite of services to support the advancement of this transformative field. 

With a team of experienced medical writers and research support specialists, mychedelica is committed to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in the psychedelic medicine space.

Psychedelic medicine is rapidly gaining recognition for its potential to treat a wide range of mental health conditions, including depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). However, the field is still in its early stages of development, and there is a critical need for high-quality medical writing and research support services to facilitate its progress.

CEO of mychedelica, Bilal Bham, commented: “We are thrilled to launch mychedelica and contribute to the advancement of psychedelic medicine.

“Our team of experienced professionals is dedicated to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in this groundbreaking field.”

mychedelica provides a comprehensive range of services, including:

Medical writing: Experienced medical writers will craft clinical trial protocols, regulatory submissions, and peer-reviewed publications, ensuring that research findings are communicated clearly and effectively.

Funding research support: Experts in grant writing and fundraising strategies will assist researchers in securing funding for their psychedelic medicine studies.

Regulatory consulting: mychedelica’s team of regulatory experts will navigate the complex regulatory landscape surrounding psychedelic medicine, ensuring that clinical trials and products comply with all applicable laws and regulations.

With its commitment to quality and innovation, mychedelica is poised to play a pivotal role in shaping the future of psychedelic medicine. The company’s services will empower researchers to conduct rigorous clinical trials, clinicians to provide effective treatments, and pharmaceutical companies to develop safe and effective psychedelic medicines.

Continue Reading

Markets & Industry

Short Wave Pharma: innovating eating disorder care with psychedelics



Short Wave Pharma: innovating eating disorder care psychedelics

Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital.

Short Wave Pharma was recently acquired by global investment firm Psych Capital. The companies are on a mission to transform mental health care, focusing on innovative approaches and treatments, including psychedelics, which are increasingly gaining acceptability as clinical research results accumulate.

Short Wave Pharma’s clinical programmes are particularly focused on Anorexia nervosa – a complex mental health condition with one of the highest fatality rates. Despite the condition being associated with high rates of suicide, it is a hugely underserved area of mental health, with no FDA-approved pharmacological drug, and a high rate of chronicity. 

See also  Psych Capital completes acquisition of Short Wave Pharma

The company has developed a novel delivery method and drug combination specifically designed to address the requirements of this vulnerable population. Short Wave focuses on methods of delivery that will be effective for Anorexia, which is a metabolic disease as well as a mental health condition. Its unique buccal film delivery method is intended to affect the brain while bypassing the liver and gut degradation through mucoadhesive absorption.

“Our goal is to alleviate, solve, and treat mental health conditions. It’s a dire need in our global society, and it’s constantly on the rise,” commented Stern. “Eating disorders are a very good example of that and we have seen a very alarming growth since COVID. 

“What drew our attention to psychedelics is that they have the potential to address very complex mental health diseases and have been designated by FDA as breakthrough medicine for life-threatening conditions.

“Because there are no current solutions, we must harness very innovative approaches and potential solutions. That’s why we started working with psychedelics which may be difficult because they are not regulated, but we don’t shy away from challenges.”

The company’s drug is based on psilocybin and another API which together utilise an expanded mechanism of action and a therapeutic effect superior to psilocybin alone, impacting more than one group of receptors in the brain. 

The delivery method is sensitive to the patients’ needs – who may not want to swallow or be injected – and is known for its high bioavailability. 

“By mucosal absorption, we are speeding the onset of the medicine and amplifying the impact which will help tackle the patients’ metabolic challenges and improve acceptance,” says Stern. 

The drug product and delivery method are currently in preparation for Phase 1 clinical studies, and in its current preclinical studies, the company is validating its delivery and expanded mechanisms of action. So far, initial safety results are positive, with a further, more in-depth toxicity study taking place. 

Psych Capital – which is a public investment and awareness platform for mental health, and has a portfolio of innovative companies – has supported Short Wave Pharma’s IP-driven approach to eating disorder care through its recent acquisition of the company.

Short Wave and Psych Capital say they are aligned in their missions to innovate mental healthcare and deliver transformative care in areas of high unmet need.

Stern commented: “We all share a passion for innovation and together have decades of experience in evaluating investments as well as scaling up R&D projects and start-ups in life sciences. 

“We have a shared commitment to alleviate the suffering from mental health. Every one of us has experienced the frustration and challenges of dealing with mental health issues.

“Together, we’re going to put this commitment into action, by bringing forth innovative solutions and developments and getting them through the first stages of development, from discovery through to early phases of clinical study. 

“With psychedelics components, this is extra challenging because of their status as scheduled drugs within a still evolving regulatory framework, which adds uncertainty to the drug development process. 

“Short Wave Pharma has operational expertise in early-stage drug development which will bring extra value to the group’s projects as they develop through our funnel and grow into promising candidates for mental healthcare.  

“We want to identify the gems, guide them through clinical development, and create the right network to attract the right partners for further development and commercialisation.”

Short Wave Pharma is planning to enter its treatment into clinical studies in 2024.

Continue Reading